Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

Share Price is delayed by 15 minutes
Get Live Data
6,865.00    170.00 (2.54%)
Bid:
6,865.00
Ask:
6,875.00
Spread: 10.00 (0.146%)
Market Cap: £5.07b
SPX Live PriceLast checked at - London Stock Exchange

Intraday Spirax-Sarco Share Chart

Trading Update

14 Nov 2024 07:00

RNS Number : 1408M
Spirax Group PLC
14 November 2024
 

14 November 2024

Trading Update

Organic revenue growth ahead of first half; full year outlook unchanged

 

Spirax Group plc issues the following update in respect of the four months ended 31 October 2024.

Economic environment

Industrial Production Growth (IP) remained weak through the third quarter, with IP in our key geographic markets lower than was forecast by CHR at the time of our first half results in August. Following downward revisions to second half IP expectations in Europe and North America, CHR's full year forecast for global IP (excluding China) is now 0.9%, down from 1.5% in August. Macroeconomic conditions in China continue to remain challenging.

Trading

Against this weak macroeconomic backdrop, we have continued to focus on driving organic sales growth and preserving our adjusted operating profit margin.

Group organic sales growth for the ten months ended 31 October was ahead of the first half of the year with sales above the prior year comparator in all three Businesses, excluding currency effects. 

In the four months ended 31 October, Steam Thermal Solutions (STS) returned to organic sales growth. Sales in China, which accounted for close to 20% of STS sales in full year 2023, continued to be impacted by the weakness in large orders highlighted during the first half, although MRO sales continued to grow.

In Electric Thermal Solutions (ETS), organic sales growth was higher than in the first half. In the Industrial Process Heating segment, we increased shipments from our strong order book through delivery of ongoing operational improvements. In the Industrial Equipment Heating segment, organic sales growth was modestly positive against a weak prior year comparator as we have yet to see a recovery in demand from customers in the Semicon sector.

In Watson-Marlow, sales to Biopharm customers were supported by our order book that has continued to normalise towards lower historic levels. Process Industries organic sales growth improved further, above the first half of the year, supporting overall organic sales growth in Watson-Marlow. 

Financial position

Net borrowings (excluding leases) at 31 October were £642 million (30 June: £718 million), with the Group net debt to EBITDA ratio at 1.7x (30 June: 1.9x).

Outlook

Our full year outlook remains unchanged from that set out at our Capital Markets event on 3 October 2024. For the Group, we expect mid-single digit organic revenue growth for the full year and an adjusted operating profit margin broadly in line with the 2023 margin of approximately 20.0% (adjusted for currency headwinds). If exchange rates at the end of October were to prevail, the headwind impact across the full year would be approximately 1% greater on both sales and adjusted operating profit than we had expected at the time of our first half results in August.

Further information:

Louisa Burdett, Chief Financial Officer

+44 (0) 1242 240281

Mal Patel, Head of Investor Relations

+44 (0) 1242 240281

 

Media:

Martin Robinson, Teneo

+44 (0) 20 7260 2700

spiraxgroup@teneo.com

 

 

 

 

 

 

 

 

 

 

About Spirax Group plc

Spirax Group (formerly Spirax-Sarco Engineering) is positioned to play a critical role in enabling the industrial transition to net zero, aligned to our Purpose to create sustainable value for all our stakeholders as we engineer a more efficient, safer and sustainable world. We put solving customers' problems at the heart of our 'total solutions' approach. Our global thermal energy and fluid technology solutions improve operating efficiency and safety in our customers' critical industrial processes. Our new-to-world decarbonisation* solutions will use our proprietary technologies to electrify boilers, for the raising of steam, as well as the electrification of other critical industrial process heating applications.

Spirax Group comprises three strong and aligned Businesses: Steam Thermal Solutions helps customers control and manage steam within their mission critical industrial applications, such as cleaning, sterilising, cooking and heating. We are helping to put food safely on the world's tables and keeping our hospitals running. Electric Thermal Solutions has proprietary technologies that deliver electrification solutions at scale in industrial settings, including for the raising of steam, supporting our customers to achieve their net zero goals. We also deliver freeze protection and defrost solutions critical to aviation and space industries and ensure thermal uniformity in Semiconductor chip manufacturing to power the critical electronic systems we rely on.  Watson‐Marlow Fluid Technology Solutions is engineering vital fluid technology solutions that optimise the efficient use of resources and support advancements in global health, such as lifesaving vaccines and gene therapies.

Spirax Group is headquartered in Cheltenham (UK). We have 37 strategically located manufacturing plants around the world and are committed to creating a safe and inclusive working culture for our 10,000 colleagues, operating in 66 countries and serving 110,000 customers globally. 

The Company's shares have been listed on the London Stock Exchange since 1959 (symbol: SPX) and we are a constituent of the FTSE 100 and the FTSE4Good Indexes.

 

* Eliminates scope 1 and 2 greenhouse gas emissions when connected to a green electricity source.

 

Further information can be found at spiraxgroup.com

 

RNS filter: Trading Update

LEI 213800WFVZQMHOZP2W17 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBJBATMTIBBTI
Date   Source Headline
2nd Aug 20238:00 amRNSBoard Appointment
1st Aug 20239:09 amRNSDirector/PDMR Shareholding
27th Jul 20239:30 amRNSChange in Director Details
26th Jun 202310:00 amRNSNotice of Investment Seminar
22nd Jun 20232:03 pmRNSHolding(s) in Company
22nd Jun 20237:00 amRNSKyoto Investment and Partnership Agreement
14th Jun 202310:42 amRNSHolding(s) in Company
9th Jun 20235:45 pmRNSHolding(s) in Company
24th May 20232:46 pmRNSHolding(s) in Company
10th May 20233:23 pmRNSResult of AGM
10th May 20237:00 amRNSAGM Trading Update
16th Mar 20234:22 pmRNSDirector/PDMR Shareholding
16th Mar 20239:00 amRNSDirector/PDMR Shareholding
15th Mar 20234:12 pmRNSDirector/PDMR Shareholding
15th Mar 20239:53 amRNSDirector/PDMR Shareholding
15th Mar 20239:48 amRNSHolding(s) in Company
13th Mar 20231:31 pmRNSDirector/PDMR Shareholding
13th Mar 202312:22 pmRNSDirector/PDMR Shareholding
9th Mar 20237:00 amRNS2022 Full Year Results
8th Mar 20233:09 pmRNSChange of Director Details
21st Feb 202310:32 amRNSHolding(s) in Company
31st Jan 20239:30 amRNSBoard Changes
30th Jan 20236:04 pmRNSHolding(s) in Company
23rd Dec 202210:31 amRNSDirector/PDMR Shareholding
1st Dec 20227:00 amRNSCompletion of the Acquisition of Durex Industries
17th Nov 20227:00 amRNSTrading Statement
27th Oct 20224:24 pmRNSDirector/PDMR Shareholding
4th Oct 20227:00 amRNSDirector/PDMR Shareholding
30th Sep 20227:00 amRNSCompletion of the acquisition of Vulcanic
28th Sep 20227:00 amRNSAcquisition of US Thermal Energy Specialist
6th Sep 202212:41 pmRNSDirector/PDMR Shareholding
11th Aug 20227:00 amRNS2022 Half Year Results
25th Jul 20227:30 amRNSVulcanic Acquisition Agreement Executed
4th Jul 202211:04 amRNSAmendment to 0126R - Director/PDMR Shareholding
4th Jul 20227:30 amRNSExclusive negotiations to acquire Vulcanic
1st Jul 202210:37 amRNSDirector/PDMR Shareholding
29th Jun 20227:00 amRNSInvestor Seminar
22nd Jun 20227:00 amRNSDirector/PDMR Shareholding
22nd Jun 20227:00 amRNSDirector/PDMR Shareholding
20th Jun 20227:00 amRNSDirector/PDMR Shareholding
23rd May 202210:48 amRNSElectric Thermal Solutions Business Update
23rd May 20229:08 amRNSDirector/PDMR Shareholding
11th May 20223:02 pmRNSResult of AGM
11th May 20227:00 amRNSAGM Trading Update
19th Apr 20223:10 pmRNSDirector/PDMR Shareholding
14th Apr 202212:00 pmRNSChange of Director Details
21st Mar 202210:10 amRNSDirector/PDMR Shareholding
17th Mar 20228:30 amRNSDirector/PDMR Shareholding
15th Mar 20223:00 pmRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNS2021 Full Year Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.